MedTrace Logo

A Study of Subcutaneous KY1005 in Healthy Volunteers

NCT04449939 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-09-30

No results posted yet for this study

Summary

Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.

Conditions

  • Immune System Diseases

Interventions

DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

Sponsors & Collaborators

  • Kymab Limited

    lead INDUSTRY

Principal Investigators

  • Adeep Puri, MBBS JCPTGP MPhil · Hammersmith Medicines Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449939 on ClinicalTrials.gov